Stoke Therapeutics, Inc. STOK Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Xenon PharmaceuticalsXENE

$6.42M-26.4%

Praxis Precision Medicines, Inc.PRAX

$1.4M—

CalAmpCAMP

$2.12M-72.7%

Harmony Biosciences Holdings, Inc.HRMY

$5.8M+225%

Maze TherapeuticsMAZE

$23.31M—

Tango TherapeuticsTNGX

$33.57M—

FAQ

What is Stoke Therapeutics, Inc.'s operating lease liabilities (total)?

Stoke Therapeutics, Inc. (STOK) reported operating lease liabilities (total) of $3.42M in Q1 2026.

How has Stoke Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?

Stoke Therapeutics, Inc.'s operating lease liabilities (total) decreased by 42.5% year-over-year, from $5.95M to $3.42M.

What is the long-term trend for Stoke Therapeutics, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s operating lease liabilities (total) has grown at a 29.3% compound annual growth rate (CAGR), from $1.15M to $4.15M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.